Fidelity Investments’s GT Biopharma GTBP Stock Holding History

Fidelity Investments’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$408	Buy	+1,000	New	+$546	﹤0.01%	5183
2024 Q2	–	Sell	-61	Closed	-$271	–	5486
2024 Q1	$271	Buy	+61	New	+$322	﹤0.01%	4896
2023 Q4	–	Sell	-5	Closed	-$36	–	5521
2023 Q3	$36	Sell	5 -763	-99%	-$6.31K	﹤0.01%	4985
2023 Q2	$7.19K	Sell	768 -928	-55%	-$9.62K	﹤0.01%	4254
2023 Q1	$28K	Hold	1,696	–	–	﹤0.01%	3692
2022 Q4	$45.5K	Sell	1,696 -29	-2%	-$1.45K	﹤0.01%	3473
2022 Q3	$91K	Sell	1,725 -116	-6%	-$8.87K	﹤0.01%	3288
2022 Q2	$165K	Buy	1,841 +129	+8%	+$9.78K	﹤0.01%	3173
2022 Q1	$148K	Buy	+1,712	New	+$151K	﹤0.01%	3324
2021 Q4	–	Sell	-4	Closed	-$1K	–	4596
2021 Q3	$1K	Buy	4 +3	+300%	+$903	﹤0.01%	4142
2021 Q2	$0	Buy	+1	New	+$416	﹤0.01%	4505

Other funds holding GTBP

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

AAP

Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SWM

SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

Fidelity Investments's GTBP Position: Q1 2026 in Review

Fidelity Investments opened a new position in GT Biopharma (GTBP) in Q1 2026: 1,000 shares worth $408. The stake represents ﹤0.01% of the portfolio and ranks #5183 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in GTBP as recently as Q1 2024.

Fidelity Investments first reported a position in GTBP in Q2 2021 and has held it in 11 quarters since. The position peaked at $165K in Q2 2022. 42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

Fidelity Investments held 1,000 shares of GT Biopharma worth $408 as of Q1 2026.
GT Biopharma was a new Fidelity Investments position in Q1 2026.
GT Biopharma made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5183 holding.
Fidelity Investments first reported a position in GT Biopharma in Q2 2021 and has held it in 11 quarters since.
Fidelity Investments's GT Biopharma position peaked at $165K in Q2 2022.
42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.